CIMERLI- ranibizumab-eqrn injection, solution

Sandoz Inc.

CIMERLI, a vascular endothelial growth factor (VEGF) inhibitor, is indicated for the treatment of patients with:

Neovascular (Wet) Age-Related Macular Degeneration (AMD) ( 1.1)
Macular Edema Following Retinal Vein Occlusion (RVO) ( 1.2)
Diabetic Macular Edema (DME) ( 1.3)
Diabetic Retinopathy (DR) ( 1.4)
Myopic Choroidal Neovascularization (mCNV) ( 1.5)

CIMERLI should be refrigerated at 2°C to 8°C (36°F to 46°F). DO NOT FREEZE. Do not use beyond the expiry date stamped on the label. Protect CIMERLI vials from light and store in the original carton until time of use.